ERBB2 and breast carcinoma: also noted increased glutamine in HER2-negative breast cancer patients 2-weeks after doxorubicin treatment, as well as reduced isovalerylcarnitine and isobutyrlcarnitine, which were significantly correlated with changes in LVEF and Troponin I respectively [56].